JOURNAL ARTICLE
RANDOMIZED CONTROLLED TRIAL
Add like
Add dislike
Add to saved papers

Acute enhancement of lower-extremity dynamic strength and flexibility with whole-body vibration.

The purpose of this investigation was to examine the acute effects of whole-body vibration (WBV) on muscular strength, flexibility, and heart rate (HR). Twenty adults (10 men, 10 women) untrained to WBV participated in the study. All subjects completed assessment of lower-extremity isokinetic torque, flexibility, and HR immediately before and after 6 minutes of WBV and 6 minutes of leg cycling ergometry (CYL), in randomized order. During WBV, subjects stood upright on a vibration platform for a total of 6 minutes. Vibration frequency was gradually increased during the first minute to a frequency of 26 Hz, which was maintained for the remaining 5 minutes. During CYL, power output was gradually increased to 50 W during the first minute and maintained at that power output for the remaining 5 minutes. Lower-extremity flexibility was determined using the sit-and-reach box test. Peak and average isokinetic torque of knee extension and flexion were measured by means of a motor-driven dynamometer with velocity fixed at 120 degrees .s. Change scores for the outcome measures were compared between treatments using Student's paired t-tests. Analysis revealed significantly greater HR acceleration with CYL (24.7 bpm) than after WBV (15.8 bpm). The increase of sit-and-reach scores after WBV (4.7 cm) was statistically greater (p < 0.05) than after CYL (0.8 cm). After WBV, increases in peak and average isokinetic torque of knee extension, 7.7% and 9.6%, were statistically greater than after CYL (p < 0.05). Average torque of knee flexion also increased more with WBV (+7.8%) than with CYL (-1.5%) (p < 0.05). The findings of this study indicate that short-term WBV standing elicits acute enhancements of lower-extremity muscular torque and flexibility, suggesting the application of this technology as a preparatory activity before more intense exercise.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app